KELLY EGUCHI: Open Payments
NPI 1013453612 · IRVINE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,189 in 134 payments from 15 companies in 2025. Trend: 2023 $2,029 · 2024 $2,786 · 2025 $3,189
Food & beverage: $3,189
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 32 | $786 |
| Neurocrine BioSciences, Inc. | 18 | $563 |
| Lundbeck LLC | 18 | $387 |
| Vanda Pharmaceuticals Inc. | 16 | $331 |
| Axsome Therapeutics, Inc. | 9 | $246 |
| Noven Therapeutics, LLC | 10 | $175 |
| Otsuka America Pharmaceutical, Inc. | 7 | $172 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $151 |
| Teva Pharmaceuticals USA, Inc. | 5 | $112 |
| Janssen Pharmaceuticals, Inc | 3 | $69 |
Products named: VRAYLAR, INGREZZA, REXULTI, FANAPT, Auvelity, Xelstrym, CAPLYTA, AUSTEDO XR.
Industry payments across CA — which companies pay providers there.
